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In this issue of Cardiology Journal Al-Mallah
et al. [1] report the seemingly counter-intuitive
result that lower LDL levels (£ 105 mg/dL) at
presentation of non-ST elevation myocardial infarc-
tion (NSTEMI) predict worse outcomes than higher
LDL levels (> 105 mg/dL). In this retrospective
study of 517 patients at a tertiary care center,
patients with LDL > 105 mg/dL had half the three-
-year mortality event rate (7.1%) that was observed
for patients with LDL £ 105 mg/dL (14.8%). The two-
-fold increased risk for patients with lower LDL re-
mained significant even after adjustment for race, prior
myocardial infarction, hypertension, diabetes, prior
aspirin, lipid lowering and beta-blocker therapy,
diastolic blood pressure, and admission HDL level.
At first glance, one might infer that this study
calls into question our understanding of LDL as
a significant risk factor for the development of co-
ronary artery disease and morbid cardiovascular
events. If these results are correct, the study
would furthermore appear to raise a question of the
value of our usual practice of targeting LDL
lowering as the cornerstone of primary and secon-
dary prevention efforts. However, the evidence for
LDL involvement in atheroma formation, its role
as a major risk factor for morbid cardiovascular
outcomes, and its value as a treatment target in
known or suspected cardiovascular disease are very
firmly established. What then accounts for the
unexpected results of the current study?
Patient selection in this study appears to have
resulted in a study population at high risk of
subsequent non-cardiac mortality. Table 5 demon-
strates non-cardiac etiologies which account for the
excess subsequent events in the low LDL group.
The low LDL group had higher six-month (10 vs.
5%) and three-year (15 vs. 7%) all-cause mortality
rates, while no difference was noted in major ad-
verse coronary events (24 vs. 21%) at six month
follow-up. The inclusion of “all cause mortality” in
the definition of major adverse coronary events by
the authors is perplexing and problematic in under-
standing the results of this study. Explanations are
needed for non-cardiac related deaths in patients
with low LDL at the presentation of NSTEMI as
well as the composition of endpoints in “major
adverse cardiac events” which included all cause
mortality. One potential explanation is that the low
LDL group, which had twice the rate of peripheral
arterial disease (PAD) (10 vs. 4%; p = 0.02), may
have been associated with deaths caused by com-
plications from PAD, vascular surgery, anesthesia,
or sepsis. Another possibility is the low LDL co-
hort may have had a greater percentage of patients
with pro-thrombotic and atherogenic conditions
such as renal failure and malignancy that contribu-
ted to the development of NSTEMI and caused
a non-cardiac related death. These co-morbid con-
ditions were not identified for analysis, and their
attributable risk remains unstudied.
The classification of the etiology of deaths by
clinical assessment is problematic. Discrepancy
exists in 20% of cases between the cause of death
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determined clinically compared with post-mortem
examination [2]. In the current study many cardiac
related events may not have been correctly
identified.  Thus, explanations for excess risk in
patients in the lower LDL group require conside-
ration of the possibility that cardiovascular events
may not have been correctly identified.
The cardiac risk profiles of the low and high
LDL groups clearly differ and lead to the conclu-
sion that the lower LDL group was at greater expec-
ted cardiac event risk. Table 1 shows that low LDL
group had an 8% excess of previous myocardial in-
farction, 11% excess of patients with diabetes, and
an 11% excess of hypertension. The reasons why
the low LDL group was loaded with greater coro-
nary artery disease risk remain unclear. Perhaps the
most striking omission in this study is the lack of
smoking rate data in the methods and results sections
in the two LDL groups, and the unsubstantiated
statement in the Figure legend that smoking was
adjusted for in the survival analysis.
The excess risk of the lower LDL group is not
apparent from the other lipid data shown in Table 2.
For example, despite a 6% lower HDL level in the
low LDL group, mean total cholesterol to HDL
(C:H) ratios (3.71 vs. 4.7) appears lower in the
lower LDL group. Whether inflammatory biomarkers
might have identified higher risk in this lower LDL
group with substantially greater PAD prevalence
remains unknown. In support of this possibility is
the demonstration of the incremental value of
hs-CRP levels in assessment of cardiovascular
disease events in patients with normal levels of LDL
[3]. Recently, the Jupiter trial demonstrated
substantial reduction of cardiovascular events with
aggressive treatment of patients with elevations of
hs-C-reactive protein despite normal LDL levels
[4]. Information about conditions associated with
elevation of inflammatory biomarkers such as family
history, metabolic syndrome, larger waist to hip
ratios, and hs-C-reactive protein levels would have
further enhanced our understanding of the vascular
and non-vascular risks of these two LDL groups
under study.
In summary this article reported patients with
a lower mean LDL (£ 105 mg/dL) who had higher
all-cause mortality rates at 6-months and three-
years compared to patients with higher mean LDL
(> 105 mg/dL). Clearly, global risk equations can
be employed to compare the cardiovascular risk in
many populations (e.g., www.heartdecision.org). To
the extent all cause mortality in this vasculopathic
population reflects non-vascular events that may or
may not have been correctly identified by etiology,
global risk and treatment bias remain considerations
to help us understand the paradoxical results of the
current study.
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